Logotype for Repligen Corporation

Repligen (RGEN) investor relations material

Repligen Bank of America Global Healthcare Conference 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Repligen Corporation
Bank of America Global Healthcare Conference 2025 summary25 Sep, 2025

Company overview and strategy

  • Positioned as an innovation leader in bioprocessing, focusing on disruptive technologies and a differentiated portfolio for biopharma and CDMO customers.

  • 80% of the portfolio faces little direct competition, creating new market segments and supporting global manufacturing with dual-sourcing strategies.

  • Achieved rapid growth through both organic innovation and 15 acquisitions over 11 years, now offering a broad product range with only a few workflow gaps.

  • Strategy centers on bioprocessing, productivity gains, disciplined M&A, and a nimble, collaborative culture that has expanded relationships with major pharma and CDMOs.

  • Tenfold revenue growth in a decade, with a tripled addressable market now at $14 billion, and strong prospects for continued outperformance.

Market performance and segment trends

  • Mid-teens topline growth in 2025, with all product franchises performing well and chromatography showing a strong recovery.

  • Order strength is broad-based, with significant recovery in both biopharma and CDMO segments, while small biotech remains muted due to funding challenges.

  • CDMO growth is robust among both large and small players, with mid-scale CDMOs showing emerging strength.

  • Product lines are expected to grow at similar rates, with targeted investment to accelerate select segments.

  • Customer base and product mix have diversified significantly, reducing concentration risk and increasing resilience.

Innovation, new modalities, and technology

  • 80% of the portfolio is differentiated, with examples like ATF technology and double-stranded RNA purification resin creating new solutions.

  • New modalities now represent 20% of the portfolio, driven by nimbleness and rapid innovation, with a focus on smaller but high-growth opportunities.

  • Diversification across modalities and programs helps offset headwinds in specific areas, such as gene therapy.

  • ATF and TFF technologies are key growth drivers, with deep expertise and strong market positioning.

  • Hardware innovation, such as real-time protein measurement, is expected to become essential for customers.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Repligen earnings date

Logotype for Repligen Corporation
Q3 202511 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Repligen earnings date

Logotype for Repligen Corporation
Q3 202511 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process. The company's bioprocessing platforms includes technologies and systems used to develop, manufacture, store, test and distribute biotherapeutic products. It offers a portfolio that is engineered to meet the strict needs of biopharmaceutical manufacturers, and scalable to service the varied needs of manufacturing across the industry. The company sells its products through direct sales force and through applications engineering groups located in North America and Europe. Repligen Corporation is based in Waltham, Massachusetts.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage